GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

Ariel Global Fund made the following comment about GSK plc (NYSE:GSK) in its Q3 2023 investor letter: “Global pharmaceutical and healthcare company, GSK plc (NYSE:GSK), also advanced in the ...

Banco Santander (BME: SAN) shares spiked over 6% on Wednesday after the lender unveiled plans for €10 billion (£8.3 billion) ...

In a 19-page letter to GSK chairman Sir Jonathan Symonds, Elliott said it had previously held off from sharing its thoughts about GSK publicly to allow the company to focus on the 23 June investor ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

AZ has confirmed that the US regulator issued a complete response letter (CRL) for PT010, a triple therapy for COPD that would compete with GSK’s already-marketed Trelegy. A spokesman for AZ tol ...

Learn more about whether Amicus Therapeutics, Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

GSK (GSK), St James’s Place (STJ), Oxford Nanopore Technologies ... cited a report that claimed the US House of Representatives had sent a letter to the new US administration calling for action ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...